[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341897-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341897-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","impact-of-neoadjuvant-androgen-deprivation-therapy-on-toxicity-in-intensity-modulated-radiation-therapy-for-prostate-cancer","Impact of neoadjuvant androgen deprivation therapy on toxicity in intensity-modulated radiation therapy for prostate cancer","","This retrospective study compared toxicities, prostate volume, and dosimetry between prostate cancer patients receiving intensity-modulated radiation therapy (IMRT) with neoadjuvant androgen deprivation therapy (NADT) for at least 3 months versus IMRT alone. Among 449 intermediate- and high-risk patients (78 Gy in 39 fractions), 320 received NADT and 129 received no ADT. The NADT group showed reduced acute and late grade 2 gastrointestinal toxicity, lower late grade 2 rectal hemorrhage, smaller prostate volume, and improved rectal/bladder dose-volume metrics. No late grade 3+ GI toxicities occurred, and NADT duration (≥12 vs \u003C12 months) did not significantly change outcomes. Results indicate NADT ≥3 months may reduce rectal toxicities through prostate shrinkage and rectal dosimetry improvement.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/impact-of-neoadjuvant-androgen-deprivation-therapy-on-toxicity-in-intensity-modulated-radiation-therapy-for-prostate-cancer/341897/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/impact-of-neoadjuvant-androgen-deprivation-therapy-on-toxicity-in-intensity-modulated-radiation-therapy-for-prostate-cancer/341897.png","ImageObject",300,407,{"name":42,"@type":43},"Rowan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What patient groups were compared in this study?","Question",{"text":63,"@type":64},"Patients with intermediate- and high-risk prostate cancer treated with 78 Gy IMRT were compared between those receiving ≥3 months of neoadjuvant androgen deprivation therapy (NADT) and those without any ADT.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which toxicity outcomes were lower with NADT?",{"text":68,"@type":64},"The NADT group had lower rates of acute and late grade 2 gastrointestinal toxicities, including a significantly lower rate of late grade 2 rectal hemorrhage. Late grade 3 or higher GI toxicities were not observed.",{"name":70,"@type":61,"acceptedAnswer":71},"How did NADT affect prostate volume and dose-volume metrics?",{"text":72,"@type":64},"NADT reduced average prostate volume by about 38% and produced significantly smaller bladder V40Gy/V50Gy and rectum V40Gy/V50Gy/V60Gy/V70Gy. The reduction in rectal toxicity was consistent with these improvements.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341897,1790171141,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Journal of Radiation Research, Vol. 65, No. 5, 2024, pp. 693–700 [https://doi.org/10.1093/jrr/rrae056](https://doi.org/10.1093/jrr/rrae056)  \nAdvance Access Publication: 17 August 2024  \nImpact of neoadjuvant androgen deprivation therapy on toxicity in intensity-modulated radiation therapy  \nfor prostate cancer  \nItsuko Serizawa 1, *, Takuyo Kozuka2, Takashi Soyano3, Kazuma Sasamura4, Tatsuya Kamima 1, Hiroaki Kunogi 1, Noboru Numao5, Shinya Yamamoto5,  \nJunji Yonese5 and Yasuo Yoshioka 1  \n1Department of Radiation Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan  \n2Department of Radiology, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan  \n3Department of Radiation Oncology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo 152-0021, Japan  \n4Department of Radiology, Musashino Red Cross Hospital, 1-26-1 Kyonancho, Musashino City, Tokyo 180-8610, Japan  \n5Department of Genitourinary Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan  \n*Corresponding author. Department of Radiation Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan. Tel: +81-3-3520-0111; Fax: +81-3-3570-0343; Email: [itsuko.serizawa@jfcr.or.jp](itsuko.serizawa@jfcr.or.jp)  \n(Received 17 April 2024; revised 2 June 2024; editorial decision 12 July 2024)  \nABSTRACT  \nThis study aimed to compare toxicities, prostate volume and dosimetry, between patients who underwent intensitymodulated radiation therapy (IMRT) combined with ≥3 months of neoadjuvant androgen deprivation therapy (NADT) and those without NADT for prostate cancer. In total, 449 patients with intermediate-and high-risk prostate cancer received 78 Gy IMRT in 39 fractions, of which 129 were treated without any ADT (non-ADT group) and  \n320 with NADT ≥3 months (NADT group). Adverse events and dose-volume indices were compared between the two groups retrospectively. The NADT group had a lower rate of acute grade 2 gastrointestinal (GI) toxicities (17% vs 25%, P= 0.063) and late grade 2 GI toxicities (P = 0.055), including a significantly lower rate of late grade 2 rectal hemorrhage (P= 0.033), compared with the non-ADT group. There were no cases of late grade 3 or higher GI toxicities. The average volume of the prostate in the NADT group was 38% smaller than that in the non-ADT group (43.7 vs 27.0 cm3, P \u003C0.001). Bladder V40Gy and V50Gy, and rectum V40Gy, V50Gy, V60Gy and V70Gy were significantly smaller in the NADT group. In the NADT group, no significant difference was observed in adverse events or dosimetry between the subgroups with NADT ≥12 and \u003C12 months. Acute and late rectal toxicities were reduced by NADT within ≥3 months in accordance with reduced prostate volume and improved rectal dosimetry.  \nThis suggests a merit of administering neoadjuvantADT ≥3 months for reducing rectal toxicities.  \nKeywords: prostate carcinoma; NADT; IMRT; radiotherapy  \nINTRODUCTION  \nRadiation therapy (RT) is a standard treatment for localized or locally advanced prostate cancer [ 1]. For intermediate-or high-risk prostate cancer, the addition of androgen deprivation therapy (ADT) to RT reduces the biochemical failure rate and increases the disease-specific survival or overall survival rate compared with RT alone [2–5]. Typically, ADTis administered for 4–6 months preceding RT (neoadjuvant ADT: NADT) for intermediate-risk prostate cancer; 1.5–3 years ADT  \nis administered for high-risk prostate cancer, including 4–6 months of NADT, concurrent and adjuvantADT [ 1–5].  \nSequencing of ADT, or prolongation of NADT, remains controversial. Using a method of an individual patient meta-analysis, several studies have compared the effect of NADTwith that ofadjuvantADT, or the effect of prolongation of the NADT duration with that of theadjuvant AD","cbCaivWW346moY1g","https://ap.wps.com/l/cbCaivWW346moY1g","pdf",644634,"English","# Abstract\n# Introduction","[{\"question\":\"What patient groups were compared in this study?\",\"answer\":\"Patients with intermediate- and high-risk prostate cancer treated with 78 Gy IMRT were compared between those receiving ≥3 months of neoadjuvant androgen deprivation therapy (NADT) and those without any ADT.\"},{\"question\":\"Which toxicity outcomes were lower with NADT?\",\"answer\":\"The NADT group had lower rates of acute and late grade 2 gastrointestinal toxicities, including a significantly lower rate of late grade 2 rectal hemorrhage. Late grade 3 or higher GI toxicities were not observed.\"},{\"question\":\"How did NADT affect prostate volume and dose-volume metrics?\",\"answer\":\"NADT reduced average prostate volume by about 38% and produced significantly smaller bladder V40Gy/V50Gy and rectum V40Gy/V50Gy/V60Gy/V70Gy. The reduction in rectal toxicity was consistent with these improvements.\"}]","Impact of neoadjuvant androgen deprivation therapy on toxicity in intensity-modulated radiation therapy for prostate cancer | PDF",1790044276,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/174106660cfd8c02d3dc582046026aae.webp",983,1269,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d9999fa842d54c3e2aa18c957e31b860.webp",982,1268,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0302917403358d00a258da74d5fa2971.webp",981,1266,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5662ad3bc58bdfe2982ba47e0d7bb899.webp",980,1265]